ImCheck publishes comprehensive overview of the development results of its first-in-class cancer immunotherapeutic targeting BTN3A to activate V?9V?2 T cells in Science Translational Medicine

Source: EurekAlert!, October 2021

Marseille, France, October 20, 2021 – ImCheck Therapeutics announced today the publication of the preclinical to clinical development of its lead immuno-oncology program, ICT01.

READ THE ORIGINAL FULL ARTICLE
Menu